

arise from two diastereomers formed for each of two orientational isomers having the dansyl group located cis to the 3' or 5' guanosine of the dinucleoside monophosphate.¹⁷ The absence of a significant intercalative interaction of the dansyl moiety with duplex DNA was demonstrated by unwinding titration experiments, which are sensitive to the mode of binding of platinum compounds.¹⁸ An unwinding angle of $13.5 \pm 1.5^\circ$ was obtained for [Pt(dansen)Cl₂] bound to pUC19 plasmid DNA. This value is essentially identical to those observed for cisplatin and [Pt(en)Cl₂], excluding [Pt(dansen)Cl₂] from the class of complexes that exhibit both covalent and intercalative interactions. Together with the demonstration of bifunctional coordination to single-stranded DNA described above, the results make it extremely unlikely that a combination of monofunctional and intercalative binding modes exists for [Pt(dansen)Cl₂].

Further evidence for the structural similarity of [Pt(dansen)Cl₂]-DNA adducts to those formed by cisplatin was obtained from the ability of the protein HMG1 to bind to restriction fragments modified by the fluorescent analogue. HMG1 binds to DNA modified by platinum complexes that form 1,2-intrastrand d(GpG) or d(ApG) cross-links, as revealed by gel mobility shift assays.¹⁹ Identical band shift studies of DNA modified with [Pt(dansen)Cl₂] indicated that HMG1 also recognizes its DNA adducts (Figure S2).

The emission spectrum of [Pt(dansen)Cl₂] is shown in Figure 1A along with that of dansylamide for comparison. The electronic absorption (dansylamide, λ_{max} 328 nm, ϵ 7060 M⁻¹ cm⁻¹; [Pt(dansen)Cl₂], λ_{max} 334 nm, ϵ 5220 M⁻¹ cm⁻¹) and emission spectra of the two compounds are not appreciably affected by the presence of a sulfone, rather than a sulfonamide, link in the dansyl moiety. The ratio of emission intensity maxima for dansylamide and [Pt(dansen)Cl₂] at 344 nm, a wavelength where the extinction coefficients are identical, is 0.44. Apparently, the propylene tether prevents efficient quenching of the fluorescence by the platinum metal center. Moreover, the emission spectrum for [Pt(dansen)Cl₂] bound to calf thymus DNA is similar to that for the free complex, as expected in the absence of intercalative binding.

The [Pt(dansen)Cl₂] compound is taken up by bacterial cells in a similar fashion to cisplatin. Figure 1B shows emission spectra for pUC19 plasmid DNA recovered from 100-mL cultures of XL1-Blue *Escherichia coli* treated with 5×10^{-5} M solutions of the complex [Pt(dansen)Cl₂] or with the free ligand dansen in phosphate-buffered saline. An emission band centered at 534 nm was observed for DNA recovered from cultures treated with [Pt(dansen)Cl₂], but not for samples isolated from cultures treated with equimolar concentrations of dansen or cisplatin. In these latter two cases, only a weak background signal due to DNA was observed. Analysis by atomic absorption spectroscopy of pUC19 DNA obtained from platinum-treated cells revealed ratios of bound drug to nucleotide (r_b) of 10^{-4} for cisplatin and 10^{-5} for [Pt(dansen)Cl₂]. Quantitation of [Pt(dansen)Cl₂] in the latter samples by fluorescence spectroscopy agreed with the atomic absorption results, confirming that the ligand remains bound to the platinum center in vivo.

The luminescence, cellular uptake, and DNA binding properties of [Pt(dansen)Cl₂] should facilitate a variety of interesting applications. In particular, this cisplatin analogue might be used to investigate its intracellular distribution, processing by DNA repair enzymes, recognition by HMG-box proteins, and other aspects of its biological chemistry in vivo.^{1,13,19} Compounds with similar optical properties, including the structurally uncharacterized compound *cis*-bis(6-aminoquinoline)dichloroplatinum(II),²⁰ have been employed to follow the compartmental localization of substrates within single cells.^{21,22} Applications requiring the

analysis of a cisplatin analogue bound to cellular DNA at r_b values considerably lower than those employed in this preliminary study should be possible with [Pt(dansen)Cl₂] or a related compound by laser excitation and recently developed, highly sensitive detection systems.^{21,23}

Acknowledgment. This work was supported by Grant CA 32134 from the National Cancer Institute. J.F.H. acknowledges the American Cancer Society for a postdoctoral fellowship and P.M.P. the Howard Hughes Medical Institute for a predoctoral fellowship. We thank Dr. Axel Masschelein and Mr. Michael Keck for helpful discussions.

Supplementary Material Available: Preparation of compounds 1-4 including spectroscopic and analytical data, Figure S1 showing the results of the digestion/HPLC analysis of a dodecanucleotide platinated with [Pt(dansen)Cl₂], and Figure S2 displaying the gel mobility shift of DNA platinated with [Pt(dansen)Cl₂] in the presence of the protein HMG1 (11 pages). Ordering information is given on any current masthead page.

(23) Sharma, M.; Jain, R.; Isac, T. V. *Bioconjugate Chem.* 1991, 2, 403.

Synthesis and Characterization of the Neutral Lanthanide Silyl Complexes (η^5 -C₅Me₅)₂LnSiH(SiMe₃)₂ (Ln = Nd, Sm)

Nora S. Radu and T. Don Tilley*

Department of Chemistry, 0506
University of California at San Diego
9500 Gilman Drive
La Jolla, California 92093-0506

Arnold L. Rheingold*

Department of Chemistry
University of Delaware
Newark, Delaware 19716

Received June 8, 1992

A number of key advances in transition-metal silicon chemistry have resulted from studies with the early transition metals.¹ In particular, it has been observed that d⁰ M-Si σ bonds readily participate in insertion² and σ -bond metathesis³ reactions, which appear to proceed via four-center, concerted additions. This suggests that f-element metal-silicon bonds would also be reactive, since they should be electronically similar to early metal-silicon

(1) Reviews: (a) Tilley, T. D. In *The Chemistry of Organic Silicon Compounds*; Patai, S., Rappoport, Z., Eds.; Wiley: New York, 1989; Chapter 24, p 1415. (b) Tilley, T. D. In *The Silicon-Heteroatom Bond*; Patai, S., Rappoport, Z., Eds.; Wiley: New York, 1991; Chapters 9, 10, pp 245, 309.

(2) (a) Campion, B. K.; Heyn, R. H.; Tilley, T. D. *Inorg. Chem.* 1990, 29, 4355. (b) Woo, H.-G.; Tilley, T. D. *J. Organomet. Chem.* 1990, 393, C6. (c) Campion, B. K.; Heyn, R. H.; Tilley, T. D. *J. Am. Chem. Soc.* 1990, 112, 2011. (d) Arnold, J.; Engeler, M. P.; Elsner, F. H.; Heyn, R. H.; Tilley, T. D. *Organometallics* 1989, 8, 2284. (e) Roddick, D. M.; Heyn, R. H.; Tilley, T. D. *Organometallics* 1989, 8, 324. (f) Arnold, J.; Tilley, T. D.; Rheingold, A. L.; Geib, S. J.; Arif, A. M. *J. Am. Chem. Soc.* 1989, 111, 149. (g) Elsner, F. H.; Tilley, T. D.; Rheingold, A. L.; Geib, S. J. *J. Organomet. Chem.* 1988, 358, 169. (h) Arnold, J.; Tilley, T. D. *J. Am. Chem. Soc.* 1987, 109, 3318. (i) Campion, B. K.; Falk, J.; Tilley, T. D. *J. Am. Chem. Soc.* 1987, 109, 2049 and references in the above.

(3) (a) Woo, H.-G.; Tilley, T. D. *J. Am. Chem. Soc.* 1989, 111, 3757. (b) Woo, H.-G.; Tilley, T. D. *J. Am. Chem. Soc.* 1989, 111, 8043. (c) Tilley, T. D. *Comments Inorg. Chem.* 1990, 10, 37. (d) Tilley, T. D.; Woo, H.-G. In *Inorganic and Organometallic Oligomers and Polymers*; Laine, R. M., Harrod, J. F., Eds.; Kluwer Publishers: Amsterdam, 1991; p 3. (e) Woo, H.-G.; Heyn, R. H.; Tilley, T. D. *J. Am. Chem. Soc.* 1992, 114, 5698. (f) Woo, H.-G.; Walzer, J. F.; Tilley, T. D. *J. Am. Chem. Soc.* 1992, 114, 7047. (g) Harrod, J. F.; Mu, Y.; Samuel, E. *Polyhedron* 1991, 11, 1239. (h) Corey, J. In *Advances in Silicon Chemistry*; Larson, G., Ed.; JAI Press, Inc.: Greenwich, CT, 1991; Vol. 1, p 327.

(18) Keck, M. V.; Lippard, S. J. *J. Am. Chem. Soc.* 1992, 114, 3386.

(19) Pil, P. M.; Lippard, S. J. *Science* 1992, 256, 243.

(20) Lu, M.; Chang, J. C.; Bergquist, B. L. *J. Inorg. Biochem.* 1991, 42, 231.

(21) Martin, P. M.; Magdelenat, H. P.; Benyahia, B.; Rigaud, O.; Katzenellenbogen, J. A. *Cancer Res.* 1983, 43, 4956.

(22) Phuong, L. T.; Grousselle, M.; Georgescauld, D.; Brienne, M. J. *Cell. Physiol. Biochem.* 1991, 1, 31.

The silyl complexes reported here, and others prepared similarly, should prove to be valuable in the characterization of Ln-Si bond reactivity. Initial reactivity studies indicate that these bonds are quite reactive. Both **1** and **2** react rapidly (≤ 5 min) with hydrogen (1 atm, benzene- d_6) to produce $[\text{Cp}^*_2\text{LnH}]_2$ and $\text{SiH}_2(\text{SiMe}_3)_2$, and with ethylene (1 atm, benzene- d_6) to produce polyethylene (by ^1H NMR spectroscopy). In the reactions with ethylene, all of **2** is consumed, but only 80% of **1**. Finally, **1** and **2** react much more rapidly with silanes than do the corresponding alkyls. For example, **1** reacts with Me_3SiH_3 (3 equiv, benzene- d_6) over 10 min at room temperature to afford $[\text{Cp}^*_2\text{SmH}]_2$, $\text{SiH}_2(\text{SiMe}_3)_2$, and $\text{Me}_3\text{SiH}_2\text{SiMe}_2$, while the analogous reaction of $\text{Cp}^*_2\text{SmCH}(\text{SiMe}_3)_2$ requires 10 min at 70°C .

Acknowledgment is made to the National Science Foundation and the donors of the Petroleum Research Fund, administered by the American Chemical Society, for financial support. T.D.T. also thanks the Alfred P. Sloan Foundation for a research fellowship (1988-1992), Union Carbide for an Innovation Recognition Award (1991-1992), and the Mobil Foundation for a financial contribution.

Supplementary Material Available: Experimental procedures and characterization data for **1** and **2** and tables of crystal, data collection, and refinement parameters, additional ORTEP drawings, bond distances and angles, anisotropic displacement parameters, and hydrogen atom coordinates for **1** (10 pages); listings of observed and calculated structure factors for **1** (9 pages). Ordering information is given on any current masthead page.

Catalytic Asymmetric Synthesis with Trans-Chelating Chiral Diphosphine Ligand TRAP: Rhodium-Catalyzed Asymmetric Michael Addition of α -Cyano Carboxylates


Masaya Sawamura, Hitoshi Hamashima, and Yoshihiko Ito*

Department of Synthetic Chemistry
Kyoto University, Kyoto 606-01, Japan


Received June 19, 1992

The synthesis of well-designed chiral phosphine ligands has played a predominant role in the recent development of catalytic asymmetric synthesis promoted by transition metal complexes.¹ Recently, we designed and synthesized a trans-chelating chiral diphosphine ligand, 2,2''-bis[1-(diphenylphosphino)ethyl]-1,1''-biferrocene (abbreviated to TRAP), which possesses planar chiralities as well as stereogenic centers.²⁻⁴ Herein, we wish to report a successful application of "TRAP" to transition metal catalyzed asymmetric synthesis, in which the rhodium complex

Scheme I



Scheme II



prepared in situ from $\text{RhH}(\text{CO})(\text{PPh}_3)_3$ and TRAP (0.1-1 mol %) was an effective catalyst for asymmetric Michael addition of α -cyano carboxylates (**1**) with vinyl ketones or acrolein (**2**) (Scheme I).⁵ To the best of our knowledge, this is the first highly enantioselective Michael addition catalyzed by a chiral transition metal complex.^{6,7}

Results are summarized in Table I. Enantioselectivities ranging from 83 to 89% were obtained for the reaction of **1c** with various vinyl ketones (**2a-f**) or acrolein (**2g**).^{8,9} The enantioselectivity depends slightly on the structure of the ester group of **1** (entries 1-3, 5), with isopropyl ester **1c** giving the highest selectivity.

(5) For the ruthenium-catalyzed aldol and Michael addition of activated nitriles, see: (a) Naota, T.; Taki, H.; Mizuno, M.; Murahashi, S.-I. *J. Am. Chem. Soc.* **1989**, *111*, 5954. Recently, the Michael addition of cyanoacetate catalyzed by $\text{RhH}(\text{CO})(\text{PPh}_3)_3$ has been reported. See: (b) Murahashi, S.-I.; Naota, T.; Maezaki, M. Presented at the 61th Annual Meeting of the Chemical Society of Japan, Yokohama, March 29-April 1, 1991, Paper 1C940. (c) Paganelli, S.; Schionato, A.; Botteghi, C. *Tetrahedron Lett.* **1991**, *32*, 2807.

(6) For catalytic asymmetric Michael addition, see: (a) Brunner, H.; Hammer, B. *Angew. Chem., Int. Ed. Engl.* **1984**, *23*, 312. (b) Brunner, H.; Kraus, J. *J. Mol. Catal.* **1989**, *49*, 133. (c) Schionato, A.; Paganelli, S.; Botteghi, C.; Chelucci, G. *J. Mol. Catal.* **1989**, *50*, 1. (d) Botteghi, C.; Schionato, A.; Rosini, C.; Salvadori, P. *J. Mol. Catal.* **1990**, *63*, 155. (e) Botteghi, C.; Paganelli, S.; Schionato, A.; Boga, C.; Fava, A. *J. Mol. Catal.* **1991**, *66*, 7. (f) Desimoni, G.; Quadrelli, P.; Righetti, P. P. *Tetrahedron* **1990**, *46*, 2927. (g) Cram, D. J.; Sogah, G. D. *J. Chem. Soc., Chem. Commun.* **1981**, 625. (h) Yura, T.; Iwasawa, N.; Narasaka, K.; Mukaiyama, T. *Chem. Lett.* **1988**, 1025.

(7) For catalytic asymmetric conjugate addition of organometallic species to α,β -unsaturated ketones, see: (a) Villacorta, G. M.; Rao, C. P.; Lippard, S. J. *J. Am. Chem. Soc.* **1988**, *110*, 3175. (b) Ahn, K.-H.; Klassen, R. B.; Lippard, S. J. *Organometallics* **1990**, *9*, 3178. (c) Soai, K.; Hayasaka, T.; Ugajin, S.; Yokoyama, S. *Chem. Lett.* **1988**, 1571. (d) Soai, K.; Yokoyama, S.; Hayasaka, T.; Ebihara, K. *J. Org. Chem.* **1988**, *53*, 4148. (e) Soai, K.; Hayasaka, T.; Ugajin, S. *J. Chem. Soc., Chem. Commun.* **1989**, 516. (f) Soai, K.; Okudo, M.; Okamoto, M. *Tetrahedron Lett.* **1991**, *32*, 95. (g) Jansen, J. F. G. A.; Feringa, B. L. *J. Org. Chem.* **1990**, *55*, 4168. (h) Bolm, C.; Ewald, M. *Tetrahedron Lett.* **1990**, *31*, 5011.

(8) Similar Michael addition of **1** with methyl acrylate or acrylonitrile took a longer reaction time, resulting in the formation of respective Michael adducts with low enantiomeric excesses (<15% ee).

(9) The reactions with aryl vinyl ketones (**2c-f**) or acrolein (**2g**) are very fast. In these cases, higher enantioselectivities are obtainable when a benzene solution of **2** is slowly added to a mixture of **1** and the catalyst in benzene.

(1) For review, see: (a) Ojima, I.; Clos, N.; Bastos, C. *Tetrahedron* **1989**, *45*, 6901. (b) Noyori, R.; Kitamura, M. In *Modern Synthetic Methods*; Scheffold, R., Ed.; Springer-Verlag: Berlin, 1989; Vol. 5, p 115. (c) Brunner, H. *Synthesis* **1988**, 645.

(2) Sawamura, M.; Hamashima, H.; Ito, Y. *Tetrahedron: Asymmetry* **1991**, *2*, 593.

(3) The trans geometry of $\text{PdCl}_2(\text{TRAP})$ and $\text{PtCl}_2(\text{TRAP})$ was confirmed by the NMR and molecular weight studies (ref 2). Recently, the X-ray crystal structure of $\text{PdBr}_2(\text{TRAP})$ has been determined, where TRAP chelates to the palladium in a P-Pd-P bite angle of 164.4° , and *trans*- $\text{RhCl}(\text{CO})(\text{TRAP})$ has been synthesized from $[\text{RhCl}(\text{CO})_2]_2$ and TRAP (unpublished results: Sawamura, M.; Hamashima, H.; Ito, Y.).

(4) It has been reported that a DIOXOP-rhodium complex can adopt trans geometry in the asymmetric hydrogenation of dehydroamino acids, but the ligand coordinates to Rh(III) as a tridentate ligand. See: (a) Brown, J. M.; Chaloner, P. A.; Descotes, G.; Glaser, R.; Lafont, D.; Sinou, D. *J. Chem. Soc., Chem. Commun.* **1979**, 611. (b) Descotes, G.; Lafont, D.; Sinou, D.; Brown, J. M.; Chaloner, P. A.; Parker, D. *Nouv. J. Chim.* **1981**, *5*, 167. Recently, Burk et al. have reported the synthesis of a series of multidentate chiral phosphorane ligands, some of which were shown to chelate to rhodium in a trans manner as tridentate ligands. See: (c) Burk, M. J.; Feaster, J. E.; Harlow, R. L. *Tetrahedron: Asymmetry* **1991**, *2*, 569.